Skip to main content
. Author manuscript; available in PMC: 2009 Jun 15.
Published in final edited form as: Stem Cells. 2009 Jan;27(1):175–182. doi: 10.1634/stemcells.2008-0583

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Survival and human cell engraftment after busulfan conditioning. (A): Kaplan-Meier estimates of survival after escalating doses of irradiation and xenotransplantation using human PB CD 34+ cells (2×10e6 cells per mouse). Group 1: 3 Gy (n=9), group 2: 2 Gy (n=8), group 3: 1.5 Gy (n=7), and group 4: 1Gy (n=10). (B): Kaplan-Meier estimates of survival after escalating doses of BU and xenotransplantation using human PB CD34+ cells (2×10e6 cells per mouse) or CB CD34+ cells (2 × 10e6 cells per mouse). Group 1: 0 mg/kg of BU (n=5), group 2: 10 mg/kg of BU (n=5), group 3: 25 mg/kg of BU (n=5); group 4: 50 mg/kg BU (n=20); group 5: 50 mg/kg of BU with 2x 10e6 CB CD34+ cells (n=21). Groups 1–4 were infused with PB CD34+ cells. (C): Human CD45+ cell engraftment following escalating doses of BU (0–50 mg/kg) using human PB CD34+ cells (2×10e6 cells per mouse); n=5 mice per cohort. (D): Human CD45+ cell engraftment after escalating doses of PB CD34+ cells following 50mg/kg BU; 5×10e5 PBCD34+ (n=7 mice); 2×10e6 PB CD34+ (n=6); 4×10e6 PB CD34+ (n=4). Bu, busulfan; CB, cord blood; Cum, cumulative; PB, peripheral blood.